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Abstract: With the emergence of the new SARS-CoV-2 virus, drug repurposing studies have gained substantial importance. Combined
with the efficacy of recent improvements in ligand- and target-based virtual screening approaches, virtual screening has become faster
and more productive than ever. In the current study, an FDA library of approved drugs and compounds under clinical investigation were
screened for their antiviral activity using the antiviral therapeutic activity binary QSAR model of the MetaCore/MetaDrug platform.
Among 6733-compound collection, we found 370 compounds with a normalized therapeutic activity value greater than a cutoff of 0.75.
Only these selected compounds were used for molecular docking studies against the SARS-CoV-2 main protease (Mpro). After initial
short (10 ns) molecular dynamics (MD) simulations with the top-50 docking scored compounds and following molecular mechanics
generalized born surface area (MM/GBSA) calculations, top-10 compounds were subjected to longer (100 ns) MD simulations and
end-point MM/GBSA estimations. Our virtual screening protocol yielded Cefuroxime pivoxetil, an ester prodrug of second-generation
cephalosporin antibiotic Cefuroxime, as being a considerable molecule for drug repurposing against the SARS-CoV-2 Mpro.
Key words: Binary QSAR, virtual screening, drug repurposing, SARS-CoV-2

1. Introduction
In December 2019, a local outbreak of pneumonia with
unknown origin was reported in Wuhan (Hubei, China),
and a novel coronavirus was soon found to be the
underlying cause (Dong et al., 2020). It has quickly become
a global pandemic and has spread to other countries,
affecting around 200 million people worldwide (WHO,
2021). Consequently, it has now become the biggest public
health emergency all around the world. Shortly after
the World Health Organization (WHO) denominated
the disease as coronavirus disease 2019 or COVID-19
(Ghosh et al., 2020). The International Committee on
Taxonomy of Viruses defined the virus as SARS-CoV-2
(Wu et al., 2020). The severity of the disease ranges from
asymptomatic cases to multiorgan failure deaths. Although
most of the patients experience some mild prodromal
symptoms 5 days after the incubation period, such as fever,
fatigue, cough and shortness of breath, in some cases, the

cytokine storm following the acute respiratory distress
syndrome induces septic shock, pulmonary embolism
and multiorgan failure associated with an increased risk
of death (Ruano‐Gallego et al., 2021). Some studies claim
the incidence of deep venous thrombosis and pulmonary
embolism in hospitalized COVID-19 patients is 25% to
58% (Erben et al., 2021). Potere et al. reported the serious
statement of the disease that mortality rate is high in
critially ill patients. (Potere et al., 2020). This disease with
its wide clinical spectrum has suddenly become more than
a global healthcare problem with its economic and social
consequences. These consequences alarmed the world to
find an urgent treatment. Unfortunately, there is currently
no globally accepted medicine for COVID-19 despite a
great number of research (Han et al., 2021).
SARS CoV-2 is a single stranded positive-sense RNA
virus that is a member of the β‐coronaviruses family
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(Kirtipal et al., 2020). SARS-CoV-2 contains approximately
30,000 nucleotide RNA sequences responsible for encoding
the entire viral proteome. The viral genome is divided into
a nonstructural protein (NSP) coding region, a helper
protein coding region and a structural protein coding
region (Kirtipal et al., 2020). Furthermore, multiple open
reading frames (ORF) are present. Structural proteins such
as spike (S), membrane (M), envelope (E), and nucleocapsid
(N) proteins are produced from the ORF’s close to the
3’-terminus of the genome and also nonstructural proteins
such as the main protease is encoded in the 5’-terminus
region (Chen et al., 2020).
The main protease (Mpro) or 3CLpro (also called
chymotrypsin-like protease or Nsp5) enzyme is the
pivotal point of drug discovery research for COVID-19.
The enzyme plays an important role in the processing
of polyproteins translated from the viral RNA and their
separation into different functional components. The
inactivation of this enzyme blocks processes such as viral
replication and transcription, stopping the virus from
reproducing in the host (Ahmed et al., 2021; Molavi et
al., 2021). The most important assignment of the Mpro is
to cleave pp1a and pp1ab, replicase 1a and replicase 1ab,
respectively. The pp1a and pp1ab are the polyproteins of
SARS CoV-2 resulting from the codification of the ORFs,
ORF1a and ORF1b. Coding these ORFs is crucial for the
virus to form its structural and nonstructural proteins.
After the production of these polyproteins, the Mpro takes
the scene and starts to cleave these polyproteins at 11 sites
with papain-like protease to create the functional proteins
of SARS CoV-2 (Shitrit et al., 2020; Guedes et al., 2021).
Mpro is a homodimeric proteolytic enzyme which
is crucial for the life cycle of SARS CoV-2. While Mpro
monomers are enzymatically inactive when separated
from each other, they become active in dimeric structure
(Silvestrini et al., 2021). Histidine at the 41st position
and Cysteine at the 145th position of the Mpro constitute
the catalytic domain of the enzyme for the binding
of substrates (Shitrit et al., 2020). Targeting the Mpro
responsible for the virus-induced apoptotic signal is the
most favorable option in inhibiting viral replication and
dysregulation of signaling cascades in infected cells (Han
et al., 2021; Rothan and Teoh, 2021).
In most studies on the catalytic activity of cysteine
protease (Nsp5), it has been reported that it mainly
depends on the interaction between Glu166 and Ser1
amino acids, and the proximity of the two protomers’ S1
subpocket and N-terminal residues, thus their connection
with dimer structures (Behnam, 2021).
Targeting the SARS CoV-2 Mpro may be a safer option,
since this protease has a cleavage site which has no
similarity with any human proteases and is special from the
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standpoint of its recognition sequence Leu-Gln (Ser, Ala,
Gly) on polyprotein 1ab (Zhang et al., 2020). Additionally,
the proposed drugs that are identified/developed against
the Mpro have a very low risk of mutation-mediated drug
resistance. The Mpro sequence is protected amongst CoV’s
because Mpro mutations are highly mortal for the virus
(Silvestrini et al., 2021). When we consider all of these
features of SARS CoV-2 Mpro such as (i) its key role in the
viral cycle, (ii) its targetable active zone in terms of both
its perishable dimer structure and blockable catalytic
dyad, (iii) its resistance against mutations, and (iv) specific
recognition site, a drug aiming Mpro can be a convenient
and secure option to tackle the SARS-CoV-2 virus.
Currently, in silico studies with computational
simulations are the first step for developing a new drug,
since this kind of virtual screening approaches make it
possible to scan huge databases in a very short time at a
very low cost for a chosen target. (Durdagi et al., 2020;
Durdağı 2020; Tutumlu et al., 2020; Kanan et al., 2021).
With the advantage of innovative in silico drug-discovery
techniques, it is possible to integrate and mine a wide
variety of high-throughput biological data developed
globally for drug repurposing, to find new indications for
existing drugs (Akhoon et al., 2019). The use of existing
drugs which have already been approved to treat different
diseases is another advantage of drug repurposing since
they have already been studied in vivo and completed
clinical trials. Therefore, their use in pandemics such as
the COVID-19 is more suitable than new molecules that
have never been tested.
In the current study, a binary QSAR model-guided
virtual screening of FDA approved compounds and
compounds in clinical investigation library which includes
around 7000 compounds are performed.
2. Methods
2.1. Ligand Preparation
A total of 7922 ligands were downloaded from NPC
library.1 In order to avoid misleading results and decrease
the nonspecificity, some filtration criteria on library
is conducted: (i) Compounds that have molecular
weight between 100 and 1000 g/mol are considered; (ii)
compounds that have more than 100 rotatable bonds are
not considered; (iii) compounds that have more than 10
hydrogen bond donor and acceptor are not considered.
Thus, the total number of molecules were decreased to
6654 before the docking simulations. These compounds
were prepared with LigPrep module (LigPrep, Schrodinger
v.2017, New York, NY, USA) of Maestro molecular
modeling package. After the ligand preparation total
number of compounds was 6733.
NPC Library (2021). Website https://tripod.nih.gov/npc)
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2.2. Protein preparation
Crystal structure of SARS-CoV-2 main protease was
downloaded from the Protein Data Bank with ID of
7CWC. The structure in apo form was prepared using
the Protein Preparation tool in the Maestro molecular
modeling suite. Initially, hydrogens were added, side
chains and loops were mended, and disulfide bonds were
created. Protonation states of the residues at physiological
pH (7.4) were assigned using PROPKA. Conformational
optimization was performed via the OPLS3e forcefield.
Homodimer stoichiometry was kept for all molecular
simulations.
2.3. Binary QSAR model
Our prefiltered ligand library was subjected to the antiviral
therapeutic activity binary QSAR model in the MetaCore/
MetaDrug platform from Clarivate Analytics. The
MetaCore/MetaDrug platform uses QSAR predictions for
pharmacokinetic and pharmacodynamic characterization
of small molecules (Dogan and Durdagi, 2020). Viral binary
QSAR model is used for the therapeutic activity predictions
of the screened compounds [model description: training
set, N = 206; test set, N = 35; sensitivity = 0.92; specificity
= 0.95; accuracy = 0.94; Matthews correlation coefficient
(MCC) = 0.88]. In the therapeutic activity prediction by
the Viral binary QSAR model, predicted activity values are
normalized between 0 and 1 (a value of more than 0.5 may
be interpreted as potential therapeutic activity). Here, we
used a higher cutoff (0.75). There were 370 compounds
among screened library.
2.4. Molecular docking
Molecular docking simulations were performed on the
surviving 370 compounds from binary QSAR screen using
the Glide/SP docking algorithm. Crucial residues at the
catalytic site of the Mpro such as His41, Cys145, and Glu166
were used to define the grid box. The thiol and hydroxyl
groups of the residues enclosed in this box were allowed to
rotate. Glide offers an optimization where van der Waals
radii can be scaled for softening potentials of nonpolar
parts of the ligands. Scaling factor was selected as 0.80 Å for
ligand atoms having less than 0.15 partial charge. Flexible
ligand sampling was used. Postdocking minimizations
were also performed as part of Glide’s docking algorithm.
2.5. Molecular dynamics simulations
Molecular dynamics (MD) simulations are used to explore
the structural and dynamical features once the compounds
bind to the infamous binding pocket of the main protease.
The Desmond program was used for this purpose. Best
scoring docked complexes were initially submerged in an
orthorhombic water box of TIP3P water models and ions
for neutralization. Salt concentration of 0.15 M was defined
to the water box. As for all the previous experiments

conducted, OPLS3e forcefield was employed for assigning
parameters. NPT ensemble was used and controlled by
the Martyna–Tobias–Klein barostat and Nosé–Hoover
thermostat, respectively. RESPA integrator is used with 2 fs
time steps. Simulations are conducted at 310 K and 1 bar.
Two different length of MD simulations are conducted: (i)
short MD simulations (10 ns); (ii) long MD simulations
(100 ns). While 100 trajectory frames are collected
throughout the simulations in short MD simulations, 1000
frames are collected in long MD simulations.
2.6. Molecular mechanics generalized Born surface area
(MM/GBSA) calculations
The MM/GBSA was used for calculating the binding
free energies of the selected hits. Hou et al. reported
that rescoring by MM/GBSA is an effective procedure to
improve the predictions of docking methods (Hou et al.,
2011). For this aim, MM/GBSA approach was preferred
in this study (Miller et al., 2012). Average binding free
energies of screened compounds were studied with MM/
GBSA method. The OPLS3e force field for molecular
mechanical energy and the surface-generalized Born
model for polar solvation energy (VSGB), as well as the
nonpolar solvation factor (GSA), were used to calculate
the endpoint energy. A total of 100 frames throughout the
simulations are extracted, then MM/GBSA was calculated
for the complexes. An average calculation of all the frames
was considered.
3. Results and discussion
Considering the off-target binding, high costs, and slow
pace of new drug discovery and development, drug
repurposing – also known as drug repositioning – has
become a more appealing method with the coronavirus
pandemic, since it involves the use of relatively safe
compounds, which could result in lower overall costs
and faster maturation timelines, which is crucial for mass
pandemics, like SARS-CoV-2. Our study aims to screen
FDA approved drugs and compounds in clinical trials for
antiviral activity and use these filtered compounds against
the SARS-CoV-2 Mpro target.
Among the 6733 compounds, 370 compounds had
normalized therapeutic activity prediction value of 0.75 or
higher (Table S1). A histogram of the therapeutic activity
prediction of the 6733-compound library revealed that the
normalized predicted activity was mostly between 0.4 and
0.6 (Figure 1). The 370 identified compounds based on
used QSAR model were used in the docking simulations.
Previously reported crucial residues, His41, Cys145
and Glu166 (Yoshino et al., 2020) were used to define the
grid-box. The thiol and hydroxyl groups of the residues
enclosed in this box were allowed to rotate. The Glide/
SP docking score ranged between –7.60 kcal/mol to
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–2.66 kcal/mol (Figure S1). Docking scores of identified
370 compounds are reported in Table S1. The best
docking score was obtained from compound Cefuroxime
axetil, which is the ester prodrug of second-generation
cephalosporin antibiotic Cefuroxime. The 3rd best scoring
compound, Cefuroxime pivoxetil is also an ester prodrug
of Cefuroxime (Scott et al., 2001).
Top-50 high docking scored compounds (Table 1) were
used in short (10 ns) MD simulations. Figures S2 shows
the protein backbone atoms RMSD versus time plot of the
selected top-10 compounds throughout 100 ns. In Figure
S3, Lig fit Prot RMSD versus time plot for the same top-10
molecules is given. The RMSD of a ligand is displayed in
Lig fit Prot when the protein-ligand complex is first fitted
on the protein backbone and the RMSD of the ligand heavy
atoms is calculated. Among the top-10 hit compounds,
Ibutamoren showed the lowest Lig fit Prot RMSD, while
Cilostamide has the most deviation. Cilostamide shows
high deviation because it loses its initial contact with
Thr24 and Thr25, instead to make interaction with Glu166
and Pro168 for last half of the 100 ns MD simulation (see
Figure S7).
Average MM/GBSA scores of these 50 hit compounds
are sorted and top-10 compounds were used in long (100
ns) MD simulations (Table 2). MM/GBSA analysis of
the trajectories for 10 ns indicates Ibutamoren as being
the ideal binder. However, for a 100 ns trajectory energy
analysis, Cefuroxime pivoxetil, shows better average free
energy of binding than the other compounds as it can
be seen in the Box and Whisker plots of the MM/GBSA
scores for the top-10 compounds in Figure 2. Given that
Cefuroxime pivoxetil has one of the top docking scores,
this compound may yield promising results. Extending
MD simulations to 100 ns has given further insight into the

changing binding energies and further fortified the results.
Figure 3 shows 2-dimensional and 3-dimensional ligand
interaction diagrams of Cefuroxime pivoxetil. Crucial
residues were found as His41, His164, Glu166, Gln189,
and Gln192. 2-dimensional and 3-dimesional interaction
diagrams of the remaining top-10 compounds are given
in the supplementary materials (Figures S4–S12). Glu166
residue was crucial for ligand binding in Ibutamoren,
which is selective ghrelin receptor and a growth hormone
secretagogue agonist, and this interaction is sustained
throughout the simulations (Figure S4). Corresponding
residues were His41, Glu166, Asp187, and Gln189 in
Atevirdine which is studied in the treatment of HIV
(Figure S5). Figure S6 shows binding mode of another
identified hit compound Ambamustine an antineoplastic
agent. A selective PDE3 inhibitor Cilostamide showed a
dramatic conformational change during the simulations.
Its interactions with Thr24 and Thr25 break off and
new contacts are established with Glu166, and Gln189
(Figure S7). Among the identified hit, Tafenoquine,
which is an antimalaria drug (Haston et al., 2019) forms
residue interactions mainly from Ser46, Glu166, and
Gln189 (Figure S8). Montirelin is a thyrotropin releasing
hormone analog (Sugimoto et al., 1996) constructs crucial
interactions with Thr26, Cys44, and Glu166 (Figure S9).
Ritonavir was also found as hit compound among identified
molecules. Its interactions mainly form from Thr26, Ser46,
Tyr118, and Glu166 (Figure S10). Corresponding main
contacts were from Met49, Asn142, Gly143, Glu166, and
Gln189 for Amplodipine which is calcium channel blocker
(Figure S11). The importance of hydrogen bonding in
ligand binding cannot be overstated. Because of their
considerable influence on drug selectivity, metabolization,
and adsorption, hydrogen-bonding properties should be

Figure 1. Histogram of therapeutic activity predictions from the MetaCore/
MetaDrug antiviral QSAR model for all 6733 compounds.
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Table 1. Docking scores of top-10 compounds at the Mpro binding site. These compounds were
initially used in short (10-ns) MD simulations. Table also shows average MM/GBSA scores of
these compounds from derived 100-trajectories throughout the simulations. Prediction of antiviral
therapeutic activity for the selected hit molecules using MetaCore/MetaDrug was also reported in
the table. Values in parenthesis – Tanimato prioritization (TP) – indicates similarity of the analyzed
structure to the most similar compound in the training set.

Compound name

10 ns
Glide/SP
docking score Antiviral (TP) MM/GBSA
SD
(kcal/mol)
(kcal/mol)

100 ns
MM/GBSA
SD
(kcal/mol)

Ibutamoren

–7.27

0.85 (49.84)

–80.07

7.34

–59.77

12.75

Cefuroxime pivoxetil

–7.42

0.79 (33.60)

–74.63

7.88

–75.08

7.31

Cefuroxime axetil

–7.60

0.79 (33.27)

–63.80

5.62

–58.40

7.15

Ambamustine

–7.23

0.79 (58.30)

–61.89

9.00

–69.17

11.52

Montirelin

–7.47

0.75 (54.38)

–59.39

3.60

–49.88

6.36

Atevirdine

–6.35

0.75 (100.00)

–58.09

4.82

–56.93

5.99

Ritonavir

–6.37

0.79 (100.00)

–54.38

11.18 –51.97

9.37

Cilostamidum

–6.45

0.77 (39.83)

–53.68

4.80

–52.13

4.76

Amlodipine

–6.60

0.78 (34.10)

–53.63

4.63

–43.80

10.42

Tafenoquine

–6.66

0.83 (40.28)

–53.40

4.98

–49.60

6.73

Figure 2. MM/GBSA score Box and Whisker plots for the selected top-10 compounds.
MM/GBSA scores of 100 frames extracted from 100 ns simulations trajectories was
considered.

considered in drug design. Compounds Ambamustine,
Cefuroxime axetil, Cefuroxime pivotexil and Atevirdine
maintain hydrogen bonding interactions with Gln189
throughout the 100 ns MD simulations (Figure 3, and
Supplementary Figures S5, S6, S12).
In geriatric patients admitted with SARS-CoV-2
infection, amlodipine, which is a dihydropyridine
calcium channel blocker, was found to be related with

significantly lower mortality and a lower probability of
intubation and mechanical breathing (Solaimanzadeh
2020). Atevirdine, as the name implies, acts as an antiviral
agent by inhibiting nonnucleoside reverse transcriptase
(Reichman et al., 1995). Construction of hydrogen bonds
with crucial residue Glu166 at the SARS-CoV-2 Mpro and
compounds Ambamustine, Amlodipine, Cefuroxime
pivoxetil, Cefuroxime axetil, Ibutamoren, Montirelin
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Figure 3. (A) 3D representation of the Cefuroxime pivoxetil at binding site. The average frame from 100 ns trajectory was used. (B) 2D
pro
interaction diagram of Cefuroxime pivoxetil at M binding site with residues around 3 Angstrom. (C) Time-dependent protein-ligand
contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction
between the protein and ligand.

and Ritonavir must be also highlighted (Figures S2–S11).
Notably, Ibutamoren, an agonist of the growth hormone
secretagogue receptor, has also been reported as having
antiviral activity against Ebola virus-like particles (Yoon
et al., 2020). Treatment with Ritonavir or Ritonavir in
combination with Lopinavir against hospitalized SARSCoV-2 patients, however, resulted in no significant effect
in clinical improvement, mortality rates or decrease in
SARS-CoV-2 viral RNA levels (Dalerba et al., 2020; Horby
et al., 2020). Furthermore, hydrophobic interactions were
assembled between His41 and Ateverdine and between
Tyr118 and Montirelin.
4. Conclusion
The reported study focuses on the binary QSAR screening of
the FDA library of approved and under clinical investigation
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compounds for potential antiviral drug candidates against
the SARS-CoV-2 main protease by drug repurposing.
Initial filtering of potential antiviral compounds using
the therapeutic activity binary QSAR models available in
the MetaCore/MetaDrug platform aimed to pick only use
molecules with potential antiviral activity, which would
hamper virus development. Our ligand-based screen
yielded 370 compounds among the 6733-compound
library, having normalized therapeutic activity value over
the cutoff of 0.75. These 370 compounds were docked
to SARS-CoV-2 Mpro and the top-50 scoring complexes
were subjected to short 10 ns MD simulations. The MD
simulations were followed by MM/GBSA calculations and
the 10-top complexes with best average MM/GBSA scores
were simulated for 100 ns and average MM/GBSA scores
were calculated from their trajectories. End-point energy
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Table 2. Docking scores of top-50 compounds at the Mpro binding site. These compounds were initially used in short (10 ns) MD simulations. Table also shows average
MM/GBSA scores of these compounds from derived 100-trajectories throughout the
simulations. Prediction of antiviral therapeutic activity for the selected hit molecules
using MetaCore/MetaDrug was also reported in the table. Values in parenthesis – Tanimato prioritization (TP) – indicates similarity of the analyzed structure to the most
similar compound in the training set.
Glide/SP
docking score Viral (TP)
(kcal/mol)

10 ns

Compound name
Ibutamoren

–7.27

0.85 (49.84)

–80.07

7.34

Cefuroxime pivoxetil

–7.42

0.79 (33.60)

–74.63

7.88

Cefuroxime axetil

–7.60

0.79 (33.27)

–63.80

5.62

Ambamustine

–7.23

0.79 (58.30)

–61.89

9.00

Montirelin

–7.47

0.75 (54.38)

–59.39

3.60

Atevirdine

–6.35

0.75 (100.00) –58.09

4.82

Ritonavir

–6.37

0.79 (100.00) –54.38

11.18

Cilostamide

–6.45

0.77 (39.83)

–53.68

4.80

Amlodipine

–6.60

0.78 (34.10)

–53.63

4.63

Tafenoquine

–6.66

0.83 (40.28)

–53.40

4.98

Regadenoson

–6.47

0.88 (71.08)

–52.93

7.22

Opanixilum

–6.70

0.77 (48.40)

–51.07

4.45

Cefsumide

–6.98

0.80 (35.26)

–49.70

3.26

Cephaloglycin

–6.47

0.79 (38.26)

–48.96

7.75

Cefdinir

–6.44

0.75 (35.16)

–48.30

4.74

Triciribine

–6.39

0.91 (70.24)

–48.20

5.17

Piritrexim

–6.41

0.81 (37.67)

–47.16

5.65

Acadesine

–6.63

0.98 (60.38)

–47.12

3.95

Glibutimine

–6.41

0.80 (34.67)

–44.01

9.47

Loxoribine

–6.80

0.89 (64.73)

–42.87

5.89

Decitabine

–6.59

0.94 (72.83)

–42.46

5.70

Amdoxovir

–6.60

0.95 (100.00) –40.80

5.80

Acrinol

–6.80

0.86 (34.88)

–40.44

6.46

Fludarabine

–6.36

0.91 (78.16)

–40.28

5.55

Tiamiprine

–6.84

0.79 (46.23)

–39.09

4.09

Penciclovir

–6.45

0.99 (100.00) –38.81

4.82

Sulfacitine

–6.39

0.76 (40.00)

–36.94

5.66

Tiazofurine

–6.65

0.89 (37.20)

–36.46

6.67

Ampyrimine phosphate

–6.49

0.84 (38.79)

–36.08

3.29

Edoxudine

–6.81

0.99 (100.00) –35.99

5.73

MM/GBSA
SD
(kcal/mol)
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Table 2. (Continued).
Glide/SP
docking score Viral (TP)
(kcal/mol)

10 ns

Compound name
Mitozolomide

–6.54

0.82 (33.33)

–33.68

9.73

Ancitabine

–6.42

0.95 (52.08)

–33.24

8.14

Zidovudine

–6.40

0.99 (100.00) –32.65

4.48

Nelarabine

–6.38

0.95 (75.00)

–32.52

5.69

Entecavir

–6.86

0.99 (100.00) –30.53

7.43

Inosine

–6.43

0.90 (87.50)

–30.51

6.10

Mitomycin

–7.40

0.85 (35.99)

–30.26

7.36

Clofarabine

–7.25

0.93 (87.45)

–29.92

13.01

Ly 163502

–6.46

0.85 (47.51)

–29.78

3.66

Gemcitabine

–6.38

0.99 (86.50)

–28.71

8.21

Mizoribine

–6.39

0.98 (55.80)

–26.26

5.26

Temodar

–6.61

0.80 (34.93)

–23.88

9.46

Navuridine

–6.38

0.99 (91.74)

–21.89

5.10

Ribavirin

–6.59

0.89 (100.00) –20.08

13.37

Dametralast

–6.66

0.83 (37.91)

–17.46

5.51

6-Methoxy-1h-Purin-2-Ylamine –6.51

0.80 (53.89)

–13.49

6.45

calculations from MD simulations revealed Cefuroxime
pivoxetil, second-generation cephalosporin antibiotic,
as being a considerable compound for drug repurposing
against the SARS-CoV-2 Mpro.
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Table S1. MetaCore/MetaDrug results of therapeutic activity
prediction for the screened compounds which have normalized
activity value of 0.75 or higher along with Glide/SP docking
scores.

Cefuroxime axetil

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–7.60
0.79 (33.27)

Montirelin

–7.47

0.75 (54.38)

Cefuroxime pivoxetil

–7.42

0.79 (33.60)

Mitomycin

–7.40

0.85 (35.99)

Flurocitabine

–7.35

0.95 (52.00)

Ibutamoren

–7.27

0.85 (49.84)

Clofarabine

–7.25

0.93 (87.45)

Ambamustine

–7.23

0.79 (58.30)

Cefsumide

–6.98

0.80 (35.26)

Entecavir

–6.86

0.99 (100.00)

Tiamiprine

–6.84

0.79 (46.23)

Edoxudine

–6.81

0.99 (100.00)

Loxoribine

–6.80

0.89 (64.73)

Acrinol

–6.80

0.86 (34.88)

Opanixilum

–6.70

0.77 (48.40)

Dametralast

–6.66

0.83 (37.91)

Tafenoquine

–6.66

0.83 (40.28)

Tiazofurine

–6.65

0.89 (37.20)

Acadesine

–6.63

0.98 (60.38)

Temodar

–6.61

0.80 (34.93)

Amdoxovir

–6.60

0.95 (100.00)

Amlodipine

–6.60

0.78 (34.10)

Decitabine

–6.59

0.94 (72.83)

Ribavirin

–6.59

0.89 (100.00)

Clevudine

–6.57

0.98 (100.00)

Floxuridine

–6.56

0.99 (100.00)

Mitozolomide

–6.54

0.82 (33.33)

6-Methoxy-1h-purin-2ylamine

–6.51

0.80 (53.89)

Ampyrimine phosphate

–6.49

0.84 (38.79)

Regadenoson

–6.47

0.88 (71.08)

Cephaloglycin

–6.47

0.79 (38.26)

Ly 163502

–6.46

0.85 (47.51)

Penciclovir

–6.45

0.99 (100.00)

Cilostamidum

–6.45

0.77 (39.83)

Cefdinir

–6.44

0.75 (35.16)

Inosine

–6.43

0.90 (87.50)

Compound name

Ancitabine

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–6.42
0.95 (52.08)

Omaciclovir

–6.42

0.99 (93.33)

Piritrexim

–6.41

0.81 (37.67)

Glibutimine

–6.41

0.80 (34.67)

Zidovudine

–6.40

0.99 (100.00)

Triciribine

–6.39

0.91 (70.24)

Mizoribine

–6.39

0.98 (55.80)

Sulfacitine

–6.39

0.76 (40.00)

Navuridine

–6.38

0.99 (91.74)

Gemcitabine

–6.38

0.99 (86.50)

Nelarabine

–6.38

0.95 (75.00)

Ritonavir

–6.37

0.79 (100.00)

Fludarabine

–6.36

0.91 (78.16)

Atevirdine

–6.35

0.75 (100.00)

Cladribine

–6.33

0.93 (87.27)

Lobucavir

–6.32

0.99 (84.15)

Leminoprazole

–6.32

0.76 (32.70)

Netivudine

–6.31

0.99 (100.00)

Peldesine

–6.31

0.76 (45.45)

Vidarabine_1

–6.30

0.91 (85.71)

Isatoribine

–6.30

0.98 (52.48)

Arabinosylthymine

–6.28

0.98 (93.27)

Telbivudine

–6.28

0.99 (100.00)

Alovudine

–6.27

0.99 (100.00)

Azacitidine

–6.26

0.94 (69.39)

Batracylin

–6.26

0.76 (34.89)

Buciclovir

–6.25

0.99 (100.00)

Tanaprogetum

–6.24

0.87 (36.88)

Sapropterin

–6.23

0.81 (49.21)

Rabeprazole

–6.22

0.79 (29.94)

Uk-52,046

–6.20

0.80 (47.79)

Etryptamine

–6.20

0.77 (36.88)

Azepexolum

–6.17

0.84 (24.77)

Binodenoson

–6.16

0.78 (80.00)

7-Amino-cephalosporanic
acid

–6.16

0.75 (31.33)

Azelnidipine

–6.15

0.75 (34.26)

Milacainide

–6.15

0.76 (44.91)

Mioflazinum

–6.15

0.75 (46.93)

Capromorelin

–6.14

0.75 (50.59)

Dacopafant

–6.14

0.78 (31.79)

Monophosphothiamine

–6.14

0.85 (28.72)

Compound name

1
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Cycotiamine

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–6.13
0.83 (29.58)

Cefetamet

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–5.88
0.76 (35.04)

Protionamidum

–6.11

Emtricitabine

–6.11

0.77 (29.88)

Tomeglovir

–5.87

0.82 (100.00)

0.99 (62.50)

Acetiamine

–5.87

0.82 (29.03)

Cytarabine

–6.10

0.99 (92.97)

Cefoxazole

–5.87

0.77 (38.05)

Amprolio

–6.06

0.88 (40.11)

Brivudine

–5.87

0.99 (100.00)

Cefadroxil

–6.06

0.76 (36.90)

Arpocox

–5.87

0.77 (56.63)

Triamterene

–6.06

0.84 (40.16)

Emorfazone

–5.87

0.82 (34.38)

Cefoxitin

–6.05

0.79 (34.69)

Pirolate

–5.87

0.75 (38.36)

Cipamfylline

–6.05

0.91 (100.00)

Trimetrexate

–5.87

0.88 (41.02)

Aditoprim

–6.05

0.76 (43.11)

Enecadinum

–5.87

0.80 (33.33)

Enviradene

–6.04

0.89 (100.00)

N acetyl d galactosamin

–5.86

0.77 (69.14)

Lansoprazole

–6.04

0.78 (29.58)

Nolatrexed

–5.86

0.79 (35.38)

Evandamine

–6.03

0.83 (29.28)

Azalanstat

–5.85

0.75 (37.96)

Euprocin

–6.03

0.75 (49.44)

Abacavir

–5.85

0.94 (100.00)

Tioguanine

–6.02

0.81 (44.52)

Pancopride

–5.85

0.80 (48.21)

Cefradine

–6.01

0.77 (36.09)

Sr 57227a

–5.85

0.75 (38.46)

Fialuridine

–6.01

0.98 (100.00)

Cns-1102

–5.85

0.86 (30.51)

Etriciguat

–6.00

0.80 (35.21)

Colfenamate

–5.85

0.77 (34.12)

Adenosine_1
(+/-)-5-(.Alpha.imidazol-1-ylbenzyl)-2methylbenzimidazole
Raluridine

–6.00

0.91 (83.88)

Epiroprim

–5.84

0.87 (39.51)

–6.00

0.76 (41.90)

Isoprazone

–5.84

0.75 (34.39)

Sorivudine

–5.84

0.99 (100.00)

–5.99

0.99 (100.00)

Esafloxacin

–5.84

0.75 (36.65)

Resiquimod

–5.99

0.83 (70.98)

Lenampicillin_1

–5.83

0.76 (41.23)

Chloroethyl thiamine

–5.98

0.84 (30.00)

Ganciclovir

–5.82

0.98 (100.00)

Ethyl loflazepate

–5.97

0.88 (38.11)

Lemildipine

–5.82

0.81 (35.02)

Cifostodine

–5.96

0.99 (69.64)

Metioprim

–5.82

0.78 (39.19)

Cocarboxylase

–5.95

0.85 (33.16)

2-Amino-6-chloropurine

–5.82

0.79 (44.37)

Airomate

–5.93

0.87 (38.70)

Mepacrine

–5.82

0.75 (45.41)

Lamivudine_1

–5.93

0.76 (100.00)

Ibacitabine

–5.81

0.99 (100.00)

Alprazolam

–5.93

0.75 (31.71)

Valganciclovir

–5.81

0.96 (78.50)

Ecenofloxacin

–5.93

0.80 (38.51)

Triazolam

–5.81

0.75 (31.10)

Rocepafant

–5.93

0.76 (34.89)

Tezacitabine

–5.81

0.99 (77.13)

Ethyl dirazepate

–5.92

0.88 (31.20)

Nsc-98700

–5.80

0.95 (87.75)

Zalcitabine

–5.92

0.99 (100.00)

Trimethoprim

–5.80

0.75 (45.83)

N-cyclopropylmelamine

–5.92

0.76 (24.22)

Tiquinamide

–5.80

0.77 (37.19)

Diaveridine

–5.91

0.75 (47.48)

Epervudine

–5.79

0.99 (100.00)

Zaleplon

–5.91

0.83 (34.33)

Nsc-4911

–5.76

0.81 (82.33)

Torcitabine

–5.90

0.99 (100.00)

Fradafiban

–5.76

0.75 (47.96)

Girodazole

–5.90

0.77 (30.17)

Maribavir

–5.75

0.91 (100.00)

Oseltamivir

–5.90

0.81 (47.24)

Vintiamol

–5.75

0.78 (32.67)

Famciclovir

–5.89

0.99 (100.00)

Cefalexin

–5.74

0.77 (37.85)

Amoxicillin

–5.74

0.78 (45.24)

Compound name

2

Compound name
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Compound name
4-(4-Fluorobenzoyl)
pyridinium
p-toluenesulfonate
4-fluorobenzyl-1hbenzimidazol-2-ylamine
Xenazoic acid
4-Nitrobenzyl
6-(2-phenoxyacetamido)
penicillanate 1-oxide
Lodenosine

Glide/SP
docking score Antiviral (TP)
(kcal/mol)

Compound name
Mosapride

–5.74

0.82 (42.35)

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–5.57
0.85 (41.11)

Didanosine
Pyrimidine, 4-methoxy-2(5-methoxy-3-methyl-1hpyrazol-1-yl)-6-methylEpetirimod esylate

–5.57

0.93 (100.00)

–5.55

0.84 (32.63)

–5.55

0.93 (82.76)

–5.73

0.86 (100.00)

–5.73

0.77 (38.10)

Imanixil

–5.54

0.79 (47.29)

Emivirine

–5.54

0.93 (100.00)

–5.73

0.95 (100.00)

Fursultiamine

–5.54

0.77 (28.38)

Clavulanic acid

–5.73

0.77 (35.83)

Ormetoprim

–5.53

0.79 (45.21)

Ethoxazolamide

–5.72

0.76 (25.85)

Pleconaril

–5.53

0.83 (100.00)

Sulfadimethoxine

–5.72

0.75 (38.96)

Idoxuridine

–5.52

0.99 (77.63)

Zaltidine

–5.72

0.83 (34.19)

Cefuroxime pivoxetil

–5.51

0.80 (33.33)

Valaciclovir

–5.71

0.96 (78.42)

Lirexapride

–5.51

0.78 (45.61)

6-Amino-5-formamido-1,3dimethyluracil

–5.71

0.75 (38.50)

Pyrazinamidum

–5.51

0.75 (25.12)

Lenampicillin

–5.70

0.76 (41.23)

Darunavir

–5.51

0.84 (87.90)

Adenosine

–5.70

0.95 (100.00)

Lamotrigine

–5.50

0.76 (51.87)

Spirgetine

–5.69

0.76 (36.67)

Tolonium

–5.50

0.76 (25.00)

Bropirimine

–5.69

0.75 (30.84)

Amprenavir

–5.49

0.96 (100.00)

Trifluridine

–5.68

0.99 (100.00)

Imexon

–5.47

0.79 (22.29)

Talviraline

–5.68

0.80 (100.00)

Adefovir

–5.46

0.96 (100.00)

Tenatoprazole

–5.65

0.76 (31.70)

Isotiquimide

–5.45

0.78 (37.37)

Aciclovir

–5.65

0.98 (100.00)

Epinastine

–5.45

0.81 (36.59)

Disuprazole

–5.64

0.79 (31.09)

Quinazosin

–5.45

0.80 (53.48)

Tetroxoprim

–5.64

0.75 (42.14)

Lomeguatribum

–5.45

0.91 (40.91)

Adenosine cyclic
3’,5’-phosphate

–5.64

0.91 (85.71)

1-(¬ø-D-arabinofuranosyl)
–5.42
pyrimidine-2,4(1h,3h)-dione

0.97 (84.30)

Ronidazole

–5.64

0.83 (27.08)

Roxifiban

–5.42

0.75 (47.06)

Fenacetinol

–5.64

0.75 (50.85)

0.99 (61.34)

–5.64

0.75 (36.51)

Stavudine

–5.63

0.97 (100.00)

–5.41

0.77 (100.00)

Brecanavir

–5.62

0.79 (100.00)

Etravirine

–5.62

0.92 (100.00)

–5.41

0.75 (53.08)

Stibamini glucosidum

–5.61

0.76 (39.56)

Cefpodoxime

–5.60

0.81 (35.07)

–5.40

0.81 (42.80)

B 4, vitami

–5.60

0.76 (47.26)

Benzyl (1-carbamoyl-2hydroxypropyl) carbamate

Troxacitabine
(S)-tetrahydro-3-furyl (m-(3(3-methoxy-4-(5-oxazolyl)
phenyl)ureido)benzyl)
carbamate
Pentisomide
6-Chloro-2-ethylamino-4methyl-4-phenyl-4h-3,1benzoxazine hydrochloride
Lanoconazole

–5.42

Iclaprim

–5.40

0.75 (28.81)

–5.60

0.83 (38.83)

Aditeren

–5.40

0.76 (44.94)

Tegafur

–5.60

0.88 (81.91)

Pramipexole

–5.38

0.82 (32.40)

4-Amino-neu5ac2en

–5.59

0.92 (89.00)

Minoxidil

–5.38

0.76 (37.57)

Opaviraline

–5.59

0.83 (100.00)

Saprisartan

–5.36

0.84 (32.37)

Sc-33643

–5.58

0.94 (36.68)

Loviride

–5.36

0.88 (100.00)

Sch-42495

–5.36

0.80 (53.62)
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Alfuzosin

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–5.35
0.79 (53.88)

Bamnidazole

–5.34

0.84 (33.33)

Azanidazole

–5.34

0.82 (26.15)

Brodimoprim
4H-thiazolo(4,5-d) azepin2-amine, 5,6,7,8-tetrahydro6-(2-propenyl)-,
dihydrochloride
Cefixime

–5.33

0.78 (43.06)

–5.33

0.82 (27.86)

–5.32

0.84 (35.11)

Sulfacecole

–5.31

Guanethidine

–5.30

Orbutopril

–5.29

0.77 (64.14)

Darodipine

–5.29

0.77 (30.72)

Adefovir_1

–5.27

0.95 (100.00)

Nepicastat

–5.27

0.77 (36.40)

Ampicillin

–5.27

0.79 (46.81)

Carbubarb

–5.26

0.81 (68.32)

Freselestat

–5.26

0.78 (32.02)

Vardenafil
Benzoic acid,
4-(acetylamino)-2-ethoxy-,
methyl ester
imiquimod

–5.25

0.76 (36.72)

–5.25

0.77 (51.72)

–5.24

0.95 (100.00)

4-Amino-2-chloro-6,7dimethoxyquinazoline

–5.24

0.78 (46.51)

Batanopride

–5.24

0.76 (44.71)

Vidarabine

–5.23

0.95 (100.00)

Compound name

Compound name
4,6-Diamino-1-(pchlorophenyl)-1,2-dihydro2,2-dimethyl-s-triazine salt
of 4,4’-methylene-bis(3hydroxy-2-naphthoic acid)
Metahexamide

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–5.15

0.78 (26.11)

–5.15

0.78 (39.46)

Epicillin

–5.15

0.79 (41.42)

Luliconazole

–5.15

0.75 (28.99)

Besipirdine

–5.14

0.76 (34.97)

0.78 (47.37)

Tolycaine

–5.14

0.75 (42.86)

0.76 (44.44)

Ethyl 2-(2-amino-1,3-thiazol4-yl)-2-hydroxyiminoacetate
2,6-Pyridinediamine,
3-(phenylazo)-,
monohydrochloride
Mapinastine
5’-Inosinic acid,
homopolymer, complex
with 5’-cytidylic acid
homopolymer (1:1)
Prosultiamine

–5.13

0.80 (25.07)

–5.12

0.75 (27.81)

–5.11

0.75 (43.56)

–5.08

0.86 (75.60)

–5.06

0.81 (29.66)

Antramycin

–5.06

0.79 (38.27)

Amisulpride

–5.05

0.79 (43.70)

Hoe 757

–5.05

0.77 (40.95)

Chlorazanil

–5.04

0.77 (40.31)

Desciclovir

–5.04

0.93 (100.00)

Primaquine

–5.03

0.77 (45.41)

Baquiloprim

–5.03

0.80 (45.09)

Ubenimex

–5.03

0.79 (66.44)

Alepride

–5.02

0.84 (43.69)

Dazopride

–5.01

0.81 (44.91)

Sildenafil
–5.01
Ethyl (z)-2-(2-aminothiazol4-yl)-2-(methoxyimino)
–5.01
acetate
Sulfaclomide
–4.99

0.76 (39.01)

5-Methyl-2-(2-nitroanilino)
thiophene-3-carbonitrile

–5.22

0.79 (28.08)

Enviroxime

–5.22

0.90 (100.00)

Amanozinum

–5.22

0.77 (43.97)

Cinitapride

–5.21

0.84 (41.71)

Diphenylguanidine

–5.20

0.77 (31.31)

Zanamivir

–5.19

0.97 (84.58)

2-Cyano-3morpholinoacrylamide

–5.19

0.79 (31.82)

Quinocide

–4.98

0.79 (45.16)

Cefdaloximum

–5.18

0.81 (35.16)

Spirotriazine hydrochloride

–4.98

0.85 (30.30)

Febuxostat

–5.18

0.81 (35.59)

Sulfaperin

–4.97

0.77 (38.42)

Guabenxan

–5.18

0.75 (46.26)

Sulfalene

–4.96

0.76 (39.91)

Palatrigine hydrochloride

–5.18

0.81 (48.83)

Furterenum

–4.96

0.88 (37.91)

Fiacitabine

–5.18

0.99 (100.00)

Lamivudine

–5.16

0.99 (57.00)

3H-1,2-dithiole-3-thione,
4-methyl-5-pyrazinyl-

–4.94

0.75 (100.00)

Fludarabine_1

–5.16

0.95 (89.87)

Taprizosinum

–4.94

0.84 (40.96)

Rociclovir

–4.94

0.99 (100.00)
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Xylamidine

Glide/SP
docking score Antiviral (TP)
(kcal/mol)
–4.93
0.78 (47.77)

Disoxaril

–4.93

0.89 (100.00)

Percodan

–4.92

0.77 (54.21)

Alamifovir

–4.91

0.85 (95.42)

Dimoxyline

–4.91

0.76 (39.75)

Romazarit

–4.91

0.77 (31.22)

3-(Cyanoimino)-3piperidinopropiononitrile

–4.90

0.78 (28.95)

Naminidil

–4.87

0.87 (30.56)

Pinacidil

–4.37

0.84 (28.57)

Fosamprenavir

–4.87

0.96 (100.00)

–4.35

0.85 (42.86)

Pyrimitate

–4.87

0.76 (29.91)

Sk&f 9267

–4.87

0.76 (28.22)

–4.30

0.85 (28.83)

Midamor

–4.86

0.77 (29.50)

Tenofovir

–4.84

0.92 (100.00)

Lauroguadinum
1-(4-Chlorophenyl)5-isopropyl-biguanide
hydrochloride
Terofenamate

–4.28

0.78 (39.80)

Dacarbazine

–4.83

0.76 (26.80)

Eclazolast

–4.26

0.83 (24.14)

Sulfamerazine sodium

–4.82

0.75 (39.83)

Trapencaine

–4.21

0.75 (46.60)

Pyrimethamine

–4.81

0.81 (55.81)

Sopromidinum

–4.18

0.79 (30.45)

Ci 994

–4.81

0.76 (68.22)

Sulfisomidine

–4.15

0.84 (41.35)

Santoquin

–4.80

0.75 (35.16)

Benoxafos

–4.10

0.85 (23.32)

Phenacainum

–4.80

0.78 (34.51)

Adenosine triphosphate

–4.07

0.95 (80.95)

Bm 41332

–4.78

0.77 (31.28)

Tiamenidine

–4.06

0.75 (22.43)

Moroxydine

–4.78

0.92 (58.44)

Carbantel

Erlotinib

–4.77

Repaglinide
Sulfasymazine

Compound name

Compound name

Glide/SP
docking score Antiviral (TP)
(kcal/mol)

8-Chloroadenosine
3’,5’-monophosphate

–4.54

0.93 (73.12)

Isamoxol

–4.52

0.86 (27.11)

Sulfaguanole

–4.52

0.79 (32.09)

Zaprinast

–4.51

0.78 (37.80)

Sulfametoxydiazine

–4.48

0.76 (37.76)

Bentiamine

–4.46

0.82 (29.71)

Aminoquinol

–4.43

0.75 (36.50)

–4.06

0.82 (41.61)

0.77 (53.78)

N’-a-(tert-butyoxycarbonyl)–4.04
n’-omega-nitro-l-arginine

0.76 (38.51)

–4.74

0.78 (47.08)

Tigemonam

–4.01

0.85 (33.25)

–4.74

0.85 (37.31)

Benphothiamine

–3.91

0.79 (31.37)

Timegadinum

–4.73

0.76 (32.52)

Nisobamate

–3.83

0.77 (32.21)

Ontazolast

–4.73

0.77 (31.58)

Silver sulfadiazine

–3.82

0.75 (39.83)

Sulfametomidine

–4.72

0.80 (37.72)

Sulfamerazine

–3.82

0.84 (37.56)

Tivirapine

–4.69

0.79 (79.13)

Atolide

–3.70

0.77 (58.40)

Guanclofine

–4.67

0.76 (30.77)

Carisoprodol

–3.69

0.77 (32.65)

Etocarlidum

–4.66

0.76 (43.36)

Carbocloralum

–3.41

0.76 (18.88)

Apraclonidine

–4.64

0.78 (28.14)

Cidofovir

–3.39

0.93 (100.00)

Cetotiamine

–4.63

0.77 (29.25)

Lorbamate

–3.33

0.84 (33.01)

Midaxifylline

–4.63

0.76 (50.60)

Maraviroc

–3.30

0.79 (100.00)

Ioxotrizoic acid

–4.62

0.77 (36.69)

Fuladectin gapromidine

–2.91

0.80 (41.04)

Poly c

–4.61

0.95 (77.83)

Amidantel

–2.66

0.76 (33.80)

Tromantadine

–4.59

0.85 (100.00)

Sulfamerazine_1

–4.58

0.84 (37.76)

Bw 1970

–4.57

0.76 (63.35)

Sulfabromomethazine sodium –4.55

0.82 (35.55)

Lapudrine

0.85 (28.42)

–4.55
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Figure S1. Glide/SP docking scores of identified 374 compounds from 6733-compound library from the
NPC database.

Figure S2. Protein backbone RMSD of selected top-10 compounds for 100 ns.
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Figure S3. Lig Fit Prot RMSD of selected top-10 compounds for 100 ns.

Figure S4. (A) 3D representation of the Ibutamoren at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction
pro
diagram of Ibutamoren at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100
ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.
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Figure S5. (A) 3D representation of the Atevirdine at binding site. The average frame from 100 ns trajectory was used. (B) 2D
pro
interaction diagram of Atevirdine at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel
throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between
the protein and ligand.
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Figure S6. (A) 3D representation of the Ambamustine at binding site. The average frame from 100 ns trajectory was used.
pro
(B) 2D interaction diagram of Ambamustine at M binding site with residues around 3 Å. (C) Time-dependent proteinligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/
broken interaction between the protein and ligand.
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Figure S7. (A) 3D representation of Cilostamide at binding site. The average frame from 100 ns trajectory was used. (B)
pro
2D interaction diagram of Cilostamidum at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand
contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken
interaction between the protein and ligand.
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Figure S8. (A) 3D representation of the Tafenoquine at binding site. The average frame from 100 ns trajectory was used. (B) 2D
pro
interaction diagram of Tafenoquine at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel
throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the
protein and ligand.
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Figure S9. (A) 3D representation of the Montirelin at binding site. The average frame from 100 ns trajectory was used. (B) 2D
pro
interaction diagram of Montirelin at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel
throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the
protein and ligand.
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Figure S10. (A) 3D representation of the Ritonavir at binding site. The average frame from 100 ns trajectory was used. (B)
pro
2D interaction diagram of Ritonavir at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand
contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken
interaction between the protein and ligand.
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Figure S11. (A) 3D representation of the Amlodipine at binding site. The average frame from 100 ns trajectory was used.
pro
(B) 2D interaction diagram of Amlodipin at M binding site with residues around 3 Å. (C) Time-dependent protein-ligand
contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken
interaction between the protein and ligand.
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Figure S12. (A) 3D representation of the Cefuroxime Axetil at binding site. The average frame from 100 ns trajectory
pro
was used. (B) 2D interaction diagram of Cefuroxime Axetil at M binding site with residues around 3 Å. (C) Timedependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottompanel shows formed/broken interaction between the protein and ligand.
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